Loading…
RenovoRx, Inc. is projected to rise to $1.15 by 2027, a +34% move from its current price of $0.86. RNXT is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 6/10/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jun 11 | $0.8276 | $0.8609 | $0.8956 | +0.11% |
| Jun 12 | $0.8151 | $0.8619 | $0.9113 | +0.22% |
| Jun 13 | $0.8058 | $0.8628 | $0.9239 | +0.33% |
| Jun 14 | $0.7982 | $0.8638 | $0.9347 | +0.44% |
| Jun 15 | $0.7917 | $0.8647 | $0.9445 | +0.55% |
| Jun 16 | $0.7859 | $0.8656 | $0.9535 | +0.66% |
| Jun 17 | $0.7807 | $0.8666 | $0.962 | +0.77% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.7807 | $0.8666 | $0.962 | +0.77% |
| Week 2 | $0.7533 | $0.8732 | $1.01 | +1.54% |
| Week 3 | $0.7343 | $0.8799 | $1.05 | +2.31% |
| Week 4 | $0.7195 | $0.8866 | $1.09 | +3.10% |
| Week 5 | $0.7074 | $0.8934 | $1.13 | +3.89% |
| Week 6 | $0.6971 | $0.9003 | $1.16 | +4.68% |
| Week 7 | $0.6882 | $0.9071 | $1.20 | +5.48% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
RenovoRx, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer.
The company was founded in 2009 and is headquartered in Mountain View, California.
RenovoRx, Inc. trades at $0.9094 and has a market capitalization of $41.01M, with a rank of 4625. The current price sits within a 30-day range that reflects modest activity for this small-cap healthcare name. The stock operates in the Healthcare sector.
A major floor 20.9% below — a decisive break under it would weaken the trend.
The nearest floor, 9.0% below — buyers have tended to step in here.
The nearest ceiling, 15.0% above — a clean break opens room to run.
A major ceiling 34.9% above — clearing it would confirm fresh momentum.
Key RNXT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RNXT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.91 | Sell | $0.9042 | Sell |
| MA 10 | $0.9216 | Sell | $0.9047 | Sell |
| MA 20 | $0.8813 | Sell | $0.8987 | Sell |
| MA 50 | $0.9194 | Sell | $0.9095 | Sell |
| MA 100 | $0.9361 | Sell | $0.9341 | Sell |
| MA 200 | $0.99 | Sell | $0.9839 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 48.45 | Neutral |
| Stoch RSI (14) | 40.50 | Neutral |
| CCI (20) | 7.57 | Neutral |
| Williams %R (14) | -56.28 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | 9.38 | Buy |
| Bollinger %B (20,2) | 0.52 | Neutral |
| Stochastic %K (14) | 43.72 | Neutral |
| TRIX (15) | -0.02 | Sell |
| Awesome (5,34) | 0.03 | Buy |
| Ultimate (7,14,28) | 43.31 | Neutral |
| Momentum (10) | 0.00 | Buy |
| Aroon Osc (25) | 28.00 | Buy |
| Hull MA (9) | 0.90 | Sell |
| ADX (14) | 12.30 | Neutral |
| ATR (14) | 0.03 | Info |
Technical sentiment is NEUTRAL with RSI(14) at 50. The 50-day simple moving average sits at $0.9392 and the 200-day simple moving average at $0.9934, suggesting the price is hovering near near-term trend lines. Support is seen at $0.783 and resistance at $1.00, framing a 30-day range from $0.7212 to $1.15.
Overall volatility remains elevated at 70%, underscoring a high-risk environment in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.783 | $0.86 | $1.28 | 0% | Neutral | |
| $0.874 | $1.15 | $1.62 | +34% | Bullish | |
| $1.20 | $1.64 | $2.43 | +91% | Bullish | |
| $1.20 | $1.70 | $2.62 | +98% | Bullish | |
| $1.08 | $1.58 | $2.51 | +84% | Bullish | |
| $1.22 | $1.84 | $3.01 | +114% | Bullish | |
| $1.20 | $1.86 | $3.11 | +116% | Bullish | |
| $1.39 | $2.21 | $3.78 | +157% | Bullish | |
| $1.76 | $2.87 | $5.01 | +233% | Bullish | |
| $1.73 | $2.89 | $5.15 | +236% | Bullish | |
| $2.47 | $4.62 | $8.91 | +437% | Bullish | |
| $3.16 | $7.01 | $15.13 | +716% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| June 2026 | $0.783 | $0.86 | $1.04 | +0.00% |
| July 2026 | $0.7654 | $0.9146 | $1.13 | +6.34% |
| August 2026 | $0.7866 | $0.9498 | $1.19 | +3.85% |
| September 2026 | $0.7522 | $0.916 | $1.16 | -3.56% |
| October 2026 | $0.7462 | $0.9158 | $1.18 | -0.03% |
| November 2026 | $0.7835 | $0.9681 | $1.26 | +5.71% |
| December 2026 | $0.7827 | $0.9733 | $1.28 | +0.54% |
Click any year to see its month-by-month RNXT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect RNXT to range from $0.783 to $1.28 through 2026. The $0.86 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The RNXT price prediction for 2027 points to an average of $1.15 (low $0.874, high $1.62) — a potential gain of +34% on today's $0.86. Momentum favours further upside here.
In 2028, RNXT is projected to trade between $1.20 and $2.43, averaging $1.64 — a potential gain of +91% from today's $0.86. That is up +43% on the projected 2027 average. Buyers look set to stay in control over this stretch.
RenovoRx, Inc.'s 2029 outlook centres on $1.70, within a $1.20 to $2.62 range. That is up +4% on the projected 2028 average. That marks a +98% change versus current levels. Momentum favours further upside here.
By 2030, RNXT could reach as high as $2.51, with a base case around $1.58 and support toward $1.08 — roughly +84% from $0.86. Buyers look set to stay in control over this stretch.
Expect RNXT to range from $1.22 to $3.01 through 2031. The $1.84 average target implies a +114% move from current prices. That is up +17% on the projected 2030 average. Momentum favours further upside here.
The RNXT price prediction for 2032 points to an average of $1.86 (low $1.20, high $3.11) — a potential gain of +116% on today's $0.86. Buyers look set to stay in control over this stretch.
In 2033, RNXT is projected to trade between $1.39 and $3.78, averaging $2.21 — a potential gain of +157% from today's $0.86. That is up +19% on the projected 2032 average. Momentum favours further upside here.
RenovoRx, Inc.'s 2034 outlook centres on $2.87, within a $1.76 to $5.01 range. That is up +30% on the projected 2033 average. That marks a +233% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, RNXT could reach as high as $5.15, with a base case around $2.89 and support toward $1.73 — roughly +236% from $0.86. Momentum favours further upside here.
Expect RNXT to range from $2.47 to $8.91 through 2040. The $4.62 average target implies a +437% move from current prices. That is up +60% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The RNXT price prediction for 2050 points to an average of $7.01 (low $3.16, high $15.13) — a potential gain of +716% on today's $0.86. Momentum favours further upside here.
Investing $1,000 in RNXT today (≈ 1,162.790698 RNXT) could be worth
$8,156.01
+$7,156.01 (+716%) by 2050 · US Dollar
Based on the average projected RNXT price of $7.01 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RNXTwould be worth at today's price.
$1,000 invested in RNXT on Jun 9, 2025 (≈ 729.927005 RNXT) would be worth
$627.74
-$372.26 (-37.2%) today · 0.63× · US Dollar
Based on a RNXT entry price of $1.37 vs. today's $0.86.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.921 | $933.77 | -6.6% |
| 1 month ago | $0.864 | $995.37 | -0.5% |
| 3 months ago | $0.82 | $1,048.78 | +4.9% |
| 6 months ago | $0.977 | $880.25 | -12.0% |
| 1 year ago | $1.37 | $627.74 | -37.2% |
| All time (4.8y) ago | $7.26 | $118.46 | -88.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RNXT forecast.
Our base-case forecast reaches $1.70 around 2029.
Implied market cap at $1.70: $76.67M
The multi-year forecast shows a bullish trajectory beginning in 2027, with the average price rising from $1.16 in 2027 to $1.53 in 2030, and continuing higher to $5.89 by 2050. Notably, 2030’s avg is $1.53 with a 68.2% ROI, 2040’s avg is $3.96 with a 336% ROI, and 2050’s avg is $5.89 with a 547.3% ROI. The sequence also includes strong upside in intermediate years (e.g., 2033 avg $2.00; 2034 avg $2.57; 2035 avg $2.56), all labeled bullish.
These figures imply a sustained, but uncertain, growth path with substantial upside potential over the long term. Investors should note the figures are estimates and not guarantees, and that volatility remains a key consideration given the 70% annualized volatility.
Tap a question to reveal the answer.
The forecast for 2030 shows an average price of $1.53 with a corresponding ROI of 68.2% and a bullish sentiment.
Forecasts indicate bullish sentiment from 2027 onward with rising average prices and ROIs, including an average of $5.89 by 2050 and a 547.3% ROI, but these are estimates and involve risk.
Yes. The 2040 forecast lists a min of $2.26, an average of $3.96, and a max of $7.31, with a 336% ROI and bullish sentiment.
Current price is $0.9094 and market cap is $41.01M, with a rank of 4625.
The 2050 forecast shows an average price of $5.89 with a max of $12.06 and a ROI of 547.3%, sentiment bullish.
RenovoRx, Inc. Community Discussion
0Share your RenovoRx, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.